Phase II trials | ||||
Regimen | Number of patients* | Tumor response rate, percent | Median overall survival, months | Reference |
Dacarbazine | 56 | 16 | 20 | Bukowski R; 1994 |
Dacarbazine (second-line) | 61 | 8 | 11.9 | Sun W; 2005 |
Etoposide | 17 | 12 | NR | Kelsen D; 1987 |
Paclitaxel¶ | 24Δ | 8 | 18 | Ansell S; 2001 |
Docetaxel | 21 | 0 | 24 | Kulke M; 2004 |
Gemcitabine | 18◊ | 0 | 11.5 | Kulke M; 2004 |
Capecitabine | 19 | 0 | 36.5 | Medley L; 2011 |
Streptozocin + fluorouracil + doxorubicin + cyclophosphamide | 56 | 30 | 10.8 | Bukowski R; 1987 |
Streptozocin + fluorouracil + cyclophosphamide | 9 | 22 | ||
Streptozocin + fluorouracil + cisplatin | 33 | 25 | 31.5§ | Turner N; 2010 |
Temozolomide + thalidomide | 15 | 7 | NR | Kulke M; 2006 |
Gemcitabine + oxaliplatin | 18 (previously treated¥) | 17 | 23.4 | Cassier P; 2009 |
Randomized trials | ||||
Regimen | Number of patients* | Tumor response rate, percent | Median overall survival, months | Reference |
Streptozocin + cyclophosphamide versus Streptozocin + fluorouracil | 47 42 | 26* 33* | 12.5 11.2 | Moertel C; 1979 |
Doxorubicin versus Streptozocin + fluorouracil | 81 80 | 21 22 | 11.1 14.9 | Engstrom P; 1984 |
Doxorubicin + fluorouracil versus Streptozocin + fluorouracil | 88 88 | 16 16 | 15.7 24.3 (p = 0.03) | Sun W; 2005 |
Do you want to add Medilib to your home screen?